Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 271 to 285 of 436 results for cardiovascular disease

  1. Type 2 diabetes: insulin degludec (ESNM25)

    Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making

  2. Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

    Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

  3. Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)

    Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages.

  4. Transcatheter endovascular closure of perimembranous ventricular septal defect (IPG336)

    Evidence-based recommendations on transcatheter endovascular closure of perimembranous ventricular septal defect. This involves inserting a small blocking device (called an occluder) into the heart.

  5. Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

    Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making

  6. Radiofrequency valvotomy for pulmonary atresia (IPG95)

    Evidence-based recommendations on radiofrequency valvotomy for pulmonary atresia. This involves making a hole in the blocked valve, and inserting and inflating a small balloon to widen it.

  7. Balloon valvuloplasty for aortic valve stenosis in adults and children (IPG78)

    Evidence-based recommendations on balloon valvuloplasty for aortic valve stenosis in adults and children. This involves inflating a balloon inserted into the narrow valve to widen it so that blood can flow out more easily.

  8. Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B (HST32)

    Evidence-based recommendations on olipudase alfa (Xenpozyme) for treating acid sphingomyelinase deficiency (Niemann–Pick disease) in people with type AB or type B.

  9. Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)

    Evidence-based recommendations on acalabrutinib (Calquence) for treating chronic lymphocytic leukaemia in adults.

  10. Neonatal parenteral nutrition (NG154)

    This guideline covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date and babies born at term, up to 28 days after their birth. Parenteral nutrition is often needed by preterm babies, critically ill babies, and babies who need surgery.

  11. Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)

    Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.

  12. Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)

    Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer in adults.

  13. Totally endoscopic robotically assisted coronary artery bypass grafting (IPG128)

    Evidence-based recommendations on totally endoscopic robotically assisted coronary artery bypass grafting (TECAB). This involves using small, remote-controlled robotic arms to carry out the grafting procedure.

  14. What is the optimal ratio of non-nitrogen energy to nitrogen in parenteral nutrition for preterm and term babies?

    associated with metabolic ill health in later life (for example, risk of cardiovascular disease, diabetes and obesity-related...

  15. MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655)

    Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.